Richmond Pharmacology is excited to confirm our attendance at AHA Scientific Sessions2025, hosted by the American Heart Association in New Orleans from 8th–10th November.
Representing Richmond at the AHA 2025:
· Dr Jörg Täubel, Chief Executive Officer
· James Rickard,Chief Scientific Officer
We look forward to connecting with attendees to discuss Richmond’s expertise in:
· Early-phasecardiovascular and cardiometabolic research
· First-in-humanand dose-ranging studies
· Novel biomarkers and digital endpoints
· Regulatory engagement and global trial delivery
· Patient-first strategies in complex CV trials
If you’re attending AHA 2025 and seeking a clinical development partner with cardiovascular expertise, arrange a meeting with us:
info@richmondpharmacology.com
Learn more: AHA 2025 | American Heart Association's Scientific Sessions
.svg){kind=small}
-min.jpg)
.jpg)
